Author:
Herrmann Ken,Bockisch Andreas,Freudenberg Lutz S.
Publisher
Springer Berlin Heidelberg
Reference55 articles.
1. Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
2. Ahmadzadehfar H, Rahbar K, Kürpig S et al (2015) Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5(1):114
3. Ahmadzadehfar H, Albers P, Bockisch A et al (2018) Lutetium-177-PSMA radioligand therapy : consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein. Urologe A 57(6):709–713
4. Albrecht S, Buchegger F, Soloviev D et al (2007) (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 34:185–196
5. Baczyk M, Czepczyński R, Milecki P, Pisarek M, Oleksa R, Sowiński J (2007) 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28:245–250